In a study by our group, we showed that another PSMA imaging agent, (18)F-DCFPyl, may be valuable for identifying metastases in patients with metastatic RAI-refractory DTC by targeting and detecting neoangiogenesis within the tumor [66]. The gene discussed is FOLH1; the disease is neoplasm.